Result of AGM

December 17, 2021
PDF Version
RNS Number : 0925W
Renalytix PLC
17 December 2021
 

Renalytix plc

("Renalytix" or the "Company") 

 

Result of AGM

 

LONDON and SALT LAKE, 17 December 2021 - Renalytix (NASDAQ: RNLX) (LSE: RENX) announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

 

The results of the AGM are detailed below:

 

Resolution

In Favour



Against



Withheld


Votes

%


Votes

%


Votes

1

36,309,096

99.95%


16,442

0.05%


40,498

2

25,272,488

70.34%


10,658,539

29.66%


26,932

3

27,437,320

76.36%


8,493,707

23.64%


26,932

4

36,289,799

99.81%


67,343

0.19%


8,894

5

36,339,057

99.95%


18,085

0.05%


8,894

6

36,337,208

99.95%


16,694

0.05%


12,134

7

36,339,655

99.95%


17,268

0.05%


9,113

8

35,826,173

98.54%


529,873

1.46%


9,990

9

27,776,213

77.27%


8,170,453

22.73%


11,293

10

35,891,613

99.94%


21,157

0.06%


45,189

 

 

For further information, please contact: 

 

Renalytix plc  

www.renalytix.com

James McCullough, CEO  

Via Walbrook PR



Stifel (Nominated Adviser, Joint Broker) 

Tel: 020 7710 7600

Alex Price / Nicholas Moore  




Investec Bank plc (Joint Broker) 

Tel: 020 7597 4000

Gary Clarence / Daniel Adams 




Walbrook PR Limited 

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: 07980 541 893 / 07584 391 303

 

About KidneyIntelX

KidneyIntelX is a first-of-kind solution that enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

 

 

 

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBUBDDSXBDGBR